Compare Crispr Therapeutics AG (CRSP) vs CubeSmart (CUBE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs CubeSmart — how do they compare? Crispr Therapeutics AG trades at $53.51 (market cap $4.88B), while CubeSmart trades at $37.93 (market cap $8.45B). The key difference: CubeSmart is the larger of the two by market cap, and CubeSmart pays a 5.65% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and CubeSmart for 89 Days on average.
| CRSP | CUBE | |
|---|---|---|
Market Cap | $4.88B | $8.45B |
Volume | 2,861,747 | 2,879,532 |
Sector | Health | Real Estate |
52-Week High | $74.92 | $42.50 |
52-Week Low | $44.34 | $35.36 |
Typical Hold Time | 77 Days | 89 Days |
Enterprise Value | $3.30B | $11.97B |
Dividend Yield | — | 5.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.41, up 2.02% with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with -$581.60M net income in 2025 and revenue volatility, though analyst consensus remains bullish with a $67.83 price target. Key catalysts include upcoming clinical data presentations for autoimmune disease therapies and CASGEVY commercialization progress.
The stock presents high-risk, high-reward potential with strong Wall Street support (57.9% buy ratings) but faces significant execution risks. Near-term performance hinges on clinical trial outcomes and revenue generation from approved therapies, while persistent cash burn and competitive pressures remain key concerns for investors.
CubeSmart (CUBE) trades at $37.73, up 1.34% with mixed technical signals showing bearish moving averages but neutral oscillators. The REIT maintains strong profitability with 29.41% net margins and consistent dividend payments. Recent Q2 2026 earnings showed operational improvement with revenue beats but FFO misses, prompting raised full-year guidance. Institutional activity remains active with several major funds increasing positions in Q2 2026.
CUBE presents a balanced opportunity with 17% upside to consensus target but faces headwinds from moderating earnings growth and high leverage. The stock offers a 5.4% dividend yield while trading at reasonable valuations (P/E 25.5). Key risks include REIT sector pressure and ongoing macroeconomic uncertainty affecting self-storage demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About CubeSmart
CubeSmart is a real estate investment trust that acquires, owns, and manages self-storage facilities throughout the United States. The company's real estate portfolio is composed of buildings with numerous enclosed storage areas for both residential and commercial customers to rent mainly on a month-by-month basis. Most of CubeSmart's facilities are located in Florida, Texas, California, New York, and Illinois. Cumulatively, these states account for both the majority of the square footage in the company's real estate portfolio and the majority of its revenue. CubeSmart derives nearly all of its revenue from rental income from tenants utilizing its storage facilities.
Read more on CUBE →
